- Companies
- NurExone Biologic
NurExone Biologic Valuation Multiples
NurExone Biologic is valued at $30M as of November 2026. In the last fiscal year, NurExone Biologic EBITDA was ($6M).
NurExone Biologic Overview
About NurExone Biologic
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
Founded
2011
HQ
Employees
16
Website
Financials (Last FY)
EV
$29M
Valuation Multiples
Start free trialNurExone Biologic Financials
NurExone Biologic reported last fiscal year revenue of - and negative EBITDA of ($6M).
In the same fiscal year, NurExone Biologic generated ($6M) in EBITDA losses and had net loss of ($6M).
Revenue (LTM)
NurExone Biologic P&L
In the most recent fiscal year, NurExone Biologic reported revenue of - and EBITDA of ($6M).
NurExone Biologic is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
NurExone Biologic Stock Performance
NurExone Biologic has current market cap of $30M, and enterprise value of $29M.
Market Cap Evolution
NurExone Biologic's stock price is $0.31.
NurExone Biologic share price decreased by 9.3% in the last 30 days.
NurExone Biologic has an EPS (earnings per share) of $-0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29M | $30M | 0.9% | -9.3% | -21.4% | - | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNurExone Biologic Valuation Multiples
NurExone Biologic trades at (4.7x) EV/EBITDA.
NurExone Biologic Financial Valuation Multiples
As of November 18, 2026, NurExone Biologic has market cap of $30M and EV of $29M.
NurExone Biologic has a P/E ratio of (4.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NurExone Biologic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


NurExone Biologic Margins & Growth Rates
NurExone Biologic decreased net profit by 26% in the last fiscal year.
NurExone Biologic Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
NurExone Biologic Operational KPIs
NurExone Biologic's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
NurExone Biologic Competitors
NurExone Biologic competitors include Nova Eye Medical, INmune Bio, Raphael Pharmaceutical, Quince Therapeutics, Nasus Pharma, Procaps Group, Rein Therapeutics, Nicox, ProMIS Neurosciences and Ortoma.
Most NurExone Biologic public comparables operate across Biopharmaceuticals, Medical Devices and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $24M | ($1M) | 1.3x | 1.2x | (22.4x) | (73.4x) | |||
| $50K | ($46M) | 303.9x | 2579.8x | (0.3x) | - | |||
| - | ($1M) | - | - | (24.2x) | - | |||
| - | ($82M) | - | - | (5.6x) | - | |||
| - | ($6M) | - | - | (3.2x) | - | |||
| $374M | ($22M) | 0.1x | 0.1x | (1.3x) | 0.3x | |||
| - | ($51M) | - | - | (0.8x) | - | |||
| $18M | $10M | 1.5x | 5.0x | 2.8x | - | |||
This data is available for Pro users. Sign up to see all NurExone Biologic competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NurExone Biologic
| When was NurExone Biologic founded? | NurExone Biologic was founded in 2011. |
| Where is NurExone Biologic headquartered? | NurExone Biologic is headquartered in Israel. |
| How many employees does NurExone Biologic have? | As of today, NurExone Biologic has over 16 employees. |
| Who is the CEO of NurExone Biologic? | NurExone Biologic's CEO is Lior Shaltiel. |
| Is NurExone Biologic publicly listed? | Yes, NurExone Biologic is a public company listed on Toronto Stock Exchange. |
| What is the stock symbol of NurExone Biologic? | NurExone Biologic trades under NRX ticker. |
| When did NurExone Biologic go public? | NurExone Biologic went public in 2022. |
| Who are competitors of NurExone Biologic? | NurExone Biologic main competitors include Nova Eye Medical, INmune Bio, Raphael Pharmaceutical, Quince Therapeutics, Nasus Pharma, Procaps Group, Rein Therapeutics, Nicox, ProMIS Neurosciences, Ortoma. |
| What is the current market cap of NurExone Biologic? | NurExone Biologic's current market cap is $30M. |
| Is NurExone Biologic profitable? | No, NurExone Biologic is not profitable. |
| What is the current net income of NurExone Biologic? | NurExone Biologic's last 12 months net income is ($6M). |
| How many companies NurExone Biologic has acquired to date? | NurExone Biologic hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies NurExone Biologic has invested to date? | NurExone Biologic hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to NurExone Biologic
Lists including NurExone Biologic
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




